Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer
PR-positivity identifies a subgroup of ER low-positive dnMBC patients with superior survival compared to ER-negative patients. First-line treatment incorporating endocrine therapy may be appropriate to consider for ER low-positive patients.
Authors
- Madelyn Klugman (ORCID: https://orcid.org/0000-0001-8059-0124)
- C. W. Marshall
- Ruizhe Chen (ORCID: https://orcid.org/0000-0003-3924-3328)
- Maya Aboumrad (ORCID: https://orcid.org/0000-0001-6140-4250)
- Jenna V. Canzoniero
- Antonio C. Wolff
- Kala Visvanathan
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Sidney Kimmel Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1007/s10549-025-07872-7
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00